Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.

Glucocorticoids up risk of vertebral fractures in RA patients

07 May 2018

The risk of vertebral fractures increases with longer duration and higher dose of oral glucocorticoids (GCs) in patients with rheumatoid arthritis (RA), but the dose and duration of GC do not contribute to the risk of hip and nonvertebral/nonhip fractures, reports a recent study.

The investigators observed 11,599 fracturs in 9,964 out of 138,240 patients with RA. Of these, 68.2 percent used oral GC for >3 months during follow-up.

Based on adjusted analysis, the risk of vertebral fractures was increased by duration of GC ≥6 months (odds ratio [OR], 1.76; p<0.01), mean dose of GC ≥2.5 mg (OR range, 1.37–1.71; p<0.01) and highest daily dose of GC ≥10 mg (OR range, 1.23–1.75; p<0.03). However, duration and dose of oral GC did not increase the risk of hip and nonvertebral/nonhip fractures in patients with RA.

Results were consistent in RA patients without osteoporosis.

To establish a retrospective cohort of patients with RA ≥19 years old, the investigators used the Korean National Healthcare Claims database from 2010. They followed these patients through December 2013 and calculated the incidence rates of total and major fractures.

Multivariable logistic regression analyses were used to evaluate the effects of GC dose and duration on fractures. The investigators also examined the influence of GC on fractures in RA patients without a history of osteoporosis.

In a 2004 study, researchers observed a dose dependence of fracture risk for hip, vertebral, nonvertebral and any fractures. Longer duration and continuous pattern of GC use showed a fivefold increased risk of hip fracture and nearly sixfold increased risk of vertebral fracture. Hip and vertebral fracture risks further increased by sevenfold and 17-fold, respectively, with the combined effect of higher dose, longer duration and continuous pattern of GC use. [Osteoporos Int 2004;15:323-328]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.